Aranesp, Procrit Potential Role In Tumor Proliferation Subject Of FDA Committee Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Studies have raised questions about the angiogenic potential of erythropoietin and its role in tumor hypoxia. Oncologic Drugs Advisory Committee is not expected to address cases of pure red blood cell aplasia.